Skip to Content
Merck
All Photos(1)

Key Documents

S9509

Supelco

(±)-Sulfinpyrazone

analytical standard

Synonym(s):

1,2-Diphenyl-4-(phenylsulfinylethyl)-3,5-pyrazolidinedione, Diphenylpyrazone

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C23H20N2O3S
CAS Number:
Molecular Weight:
404.48
EC Number:
MDL number:
UNSPSC Code:
41116107
PubChem Substance ID:
NACRES:
NA.24

grade

analytical standard

Quality Level

Assay

≥99%

technique(s)

HPLC: suitable
gas chromatography (GC): suitable

application(s)

cleaning products
cosmetics
food and beverages
forensics and toxicology
personal care
pharmaceutical (small molecule)
veterinary

format

neat

SMILES string

O=C1C(CCS(=O)c2ccccc2)C(=O)N(N1c3ccccc3)c4ccccc4

InChI

1S/C23H20N2O3S/c26-22-21(16-17-29(28)20-14-8-3-9-15-20)23(27)25(19-12-6-2-7-13-19)24(22)18-10-4-1-5-11-18/h1-15,21H,16-17H2

InChI key

MBGGBVCUIVRRBF-UHFFFAOYSA-N

Gene Information

Looking for similar products? Visit Product Comparison Guide

General description

Sulfinpyrazone is a 1,3-dicarbonyl uricosuric drug used in the treatment of hyperuricemia associated with gout.

Application

Refer to the product′s Certificate of Analysis for more information on a suitable instrument technique. Contact Technical Service for further support.

Pictograms

Exclamation mark

Signal Word

Warning

Hazard Statements

Precautionary Statements

Hazard Classifications

Acute Tox. 4 Oral

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Screening of xanthine oxidase inhibitor from selected edible plants and hypouricemic effect of Rhizoma Alpiniae Officinarum extract on hyperuricemic rats
Lin L, et al.
Journal of functional foods, 50(1), 26-36 (2018)
High-performance liquid chromatography-tandem mass spectrometry in the identification and determination of phase I and phase II drug metabolites
Holcapek M, et al.
Analytical and Bioanalytical Chemistry, 391(1), 59-78 (2008)
D H Solomon et al.
Annals of the rheumatic diseases, 67(5), 609-613 (2007-08-31)
Uric acid lowering therapy (UALT) is considered a chronic treatment for gout. Relatively little is known about adherence to UALT. We assessed adherence with UALT over a 1-year study period among 9823 older adults enrolled in a pharmacy benefit program.
Tetsuya Oguri et al.
Molecular cancer therapeutics, 7(5), 1150-1155 (2008-05-01)
We used the paclitaxel-resistant human small cell lung cancer subline PC-6/TAX1-1, selected from PC-6 cells by paclitaxel, to test whether MRP7/ABCC10 (ABCC10) confers paclitaxel resistance. We found that gene expression of both ABCB1/MDR1 (ABCB1) and ABCC10 was higher in PC-6/TAX1-1
Leslie R Harrold et al.
Arthritis research & therapy, 11(2), R46-R46 (2009-03-31)
Adherence to urate-lowering drugs (ULDs) has not been well evaluated among those with gout. Our aim was to assess the level and determinants of non-adherence with ULDs prescribed for gout. We identified persons using two integrated delivery systems aged 18

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service